Form 4: HealthEquity Director Robert Selander Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Robert Selander exercised stock options and sold shares of HealthEquity, Inc. under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Robert W. Selander, a director of HealthEquity, Inc., executed a stock option to acquire 12,500 shares of common stock at a price of $28.68 on February 10, 2025.
- On the same day, Selander sold 3,752 shares at a weighted average price of $110.9826, with prices ranging from $110.62 to $111.60.
- Additionally, he sold 1,998 shares at a weighted average price of $111.872, with prices ranging from $111.62 to $112.50.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on July 9, 2024.
- Following these transactions, Selander directly owns 78,219 shares of HealthEquity, Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors, which is important for investor confidence and regulatory compliance.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
- Similar filings are made by executives and directors at companies like UnitedHealth Group (UNH) and CVS Health (CVS) when they trade their company's stock.
- The use of 10b5-1 trading plans is also a common practice to avoid accusations of illegal insider trading, aligning with industry best practices for corporate governance.
Stakeholder Impact
- The disclosure of insider trading activity provides transparency to shareholders.
- The transactions themselves may have a minor impact on the stock price, depending on market perception.
Key Dates
| Date | Description |
|---|---|
| July 09, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/10/2025 | Date of stock option exercise and share sales |
| 02/11/2025 | Date of signature of the Form 4 filing |
| 09/29/2025 | Expiration date of the stock option |
Keywords
HealthEquity, HQY, Robert Selander, stock option, Rule 10b5-1, insider trading, Form 4, share sale, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.